Literature DB >> 10682970

One-year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy.

R S Kaiser1, M G Maguire, J E Grunwald, D Lieb, B Jani, A J Brucker, A M Maguire, A C Ho, S L Fine.   

Abstract

PURPOSE: To describe the clinical features and complications of diabetic retinopathy, visual acuity, and number of repeat treatments after panretinal photocoagulation for proliferative diabetic retinopathy in a tertiary care center.
METHODS: A cohort study was conducted with data collection from medical records of patients undergoing panretinal photocoagulation between 1985 and 1995 at the Scheie Eye Institute; 297 eyes of 186 patients were eligible for study.
RESULTS: The presence of neovascularization of the disk at baseline, an earlier onset of diabetes, and a shorter duration of disease before panretinal photocoagulation were the strongest risk factors for needing an additional panretinal photocoagulation treatment. Sixty-two percent of eyes with poor visual acuity (< or =20/200) at baseline still had poor visual acuity at 1 year, and 76% with good visual acuity (> or =20/40) at baseline maintained good visual acuity at 1 year. Poor vision at baseline was the only risk factor for having poor vision at 1 year. Vitreous hemorrhage was present in 44% of eyes at baseline. New vitreous hemorrhage developed in 37% of eyes during the first year after panretinal photocoagulation. A traction retinal detachment was present in 4% of eyes at baseline and newly developed in 6% of eyes during follow-up. A repeat panretinal photocoagulation treatment was performed in 39% of eyes after initial treatment. A vitrectomy was performed in 10% of eyes from baseline through the 1-year follow-up visit.
CONCLUSIONS: The data from this study are useful for counseling patients with respect to likely visual outcome, possibility of major complications from proliferative diabetic retinopathy, and the chance of undergoing additional laser treatment after panretinal photocoagulation.

Entities:  

Mesh:

Year:  2000        PMID: 10682970     DOI: 10.1016/s0002-9394(99)00322-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  11 in total

1.  Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4.

Authors:  M M K Muqit; G R Marcellino; D B Henson; L B Young; G S Turner; P E Stanga
Journal:  Eye (Lond)       Date:  2011-08-05       Impact factor: 3.775

2.  Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment.

Authors:  J Fernando Arevalo; Martin A Serrano; Juan D Arias
Journal:  World J Diabetes       Date:  2014-10-15

3.  Pain score of patients undergoing single spot, short pulse laser versus conventional laser for diabetic retinopathy.

Authors:  Ahmad Mirshahi; Alireza Lashay; Mehdi Roozbahani; Masoud Aghsaei Fard; Saber Molaie; Meysam Mireshghi; Mohamad Mehdi Zaferani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-11       Impact factor: 3.117

4.  Extended targeted retinal photocoagulation versus conventional pan-retinal photocoagulation for proliferative diabetic retinopathy in a randomized clinical trial.

Authors:  Homayoun Nikkhah; Hossein Ghazi; Mohammad Reza Razzaghi; Saeed Karimi; Alireza Ramezani; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2017-02-06       Impact factor: 2.031

5.  Multimodal characterization of proliferative diabetic retinopathy reveals alterations in outer retinal function and structure.

Authors:  Grace E Boynton; Maxwell S Stem; Leon Kwark; Gregory R Jackson; Sina Farsiu; Thomas W Gardner
Journal:  Ophthalmology       Date:  2015-01-17       Impact factor: 12.079

6.  Vitreous hemorrhage in diabetic eyes previously treated with panretinal photocoagulation.

Authors:  Guy Kleinmann; David Hauser; Edna Schechtman; Gennady Landa; Amir Bukelman; Ayala Pollack
Journal:  Int Ophthalmol       Date:  2007-07-10       Impact factor: 2.031

7.  The use of antivascular endothelial growth factor agents in the perioperative period in diabetic vitrectomy.

Authors:  Nakhleh E Abu-Yaghi; Sophie J Bakri
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01

8.  Vitreous hemorrhage in diabetes patients with proliferative diabetic retinopathy undergoing hemodialysis.

Authors:  Yusuke Kameda; Ko Hanai; Yasuko Uchigata; Tetsuya Babazono; Shigehiko Kitano
Journal:  J Diabetes Investig       Date:  2019-11-09       Impact factor: 4.232

9.  Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy.

Authors:  Yong Woon Shin; Yoon Jung Lee; Byung Rho Lee; Hee Yoon Cho
Journal:  Korean J Ophthalmol       Date:  2009-12-04

Review 10.  Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Authors:  Jonathan M Smith; David H W Steel
Journal:  Cochrane Database Syst Rev       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.